stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) EV/FCF
As of 5 November 2026, GeneDx Holdings Corp. (WGS) trades at a EV/FCF of −25.0×. Over the past ten years it has ranged from −244× (April 2025) to 4,464× (September 2025); the current reading is higher than 20% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 253× | — |
| FY2024 | −58.2× | — |
| FY2023 | 0.1× | (78.80%) |
| FY2022 | 0.3× | (80.61%) |
| FY2021 | 1.8× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | −26.4× | — |
| Mar 2026 | −63.2× | — |
| Dec 2025 | 253× | 30.24% |
| Sep 2025 | 194× | (93.70%) |
| 19 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ADPT Adaptive Biotechnologies Corporation compare | −494× |
| NEO NeoGenomics, Inc. compare | −96.9× |
| FRNM Freenome, Inc compare | −27.7× |
| WGS GeneDx Holdings Corp. | −25.0× |
| PSNL Personalis, Inc. compare | −14.1× |
| OPK OPKO Health, Inc. compare | −9.6× |
| VCYT Veracyte, Inc. compare | 9.0× |
| CDNA CareDx, Inc. compare | 64.7× |
| CSTL Castle Biosciences, Inc. compare | 198× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement